A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS

Inclusion Criteria

• •Concurrent Medication:
• •Allowed:
• •Zidovudine (AZT).
• •Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more.
• •Aerosolized pentamidine.
• •Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril.
• •Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug.
• •Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol.
• •Patients must have the following:
• •Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained.
• •Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up).
• •Prior Medication:
• •Allowed:
• •Diclazuril.